Structure Encountered
Kali Therapeutics
Develops masked T-cell engagers for B-cell-mediated autoimmune disease.
Kali Therapeutics will present KT502, its CD19xCD3 bispecific TCE for autoimmune disease, at EULAR 2026 in London.
SIGNAL·Preclinical data oral presentation·EULAR 2026 oral presentation·SCORE 74·19 MAY 2026 · 12:47 UTC
● CAPTURE — IMAGE INCOMINGFRAME 01 / 01
STRUCT. / KALI THERAPEUTICS
/ San Mateo, California, United States
CAPT. / 19.05.26 12:47:05Z
SIGNAL / 74 / 100
Image relayed by The Biotech Voyager during pass over structure Kali Therapeutics. Resolution as transmitted.
001Vital Statistics
DATA LOCKED
Designation
Kali Therapeutics
Coordinates
San Mateo, California, United States
Stage
Preclinical
Type
Therapeutics
Modalities
bispecific · trispecific · protein therapeutic · biologic
Therapeutic area
Autoimmune · Immunology · Rheumatology
002Signature Detected
EVENT DETECTED
Event type
Preclinical data oral presentation
Magnitude
EULAR 2026 oral presentation
Lead
Kali Therapeutics
Participating
EULAR 2026 Annual Congress, London, June 3-6, 2026
003Architecture
PLATFORM PROFILE
Target class
CD19 (pan-B-cell marker) and CD3 (T-cell engagement), with a masked CD3 arm intended to dampen cytokine release. KT502 targets B cells in both peripheral blood and tissue compartments for immune reset in autoimmune disease.
Differentiator
Most CD19xCD3 TCEs deliver cytokine release storms that limit dosing. Kali's KT502 uses a proprietary CD3 masking platform to dampen cytokine response while preserving B-cell killing. Subcutaneous formulation, designed for tissue compartment depletion not the bloodstream pool alone. KT502 is the bispecific complement to the trispecific KT501 already licensed to Sanofi.
Lead asset
KT502, CD19xCD3 bispecific TCE with masked CD3, subcutaneous, preclinical
Pipeline depth
2 disclosed TCE assets: KT501 (CD19xBCMAxCD3 trispecific, Phase 1a RA, licensed to Sanofi $1.23B March 2026), KT502 (CD19xCD3 bispecific, preclinical). Both built on proprietary CD3 masking platform.
004Voyager Assessment
MACHINE-GENERATED
Two months after Sanofi paid $180M upfront for KT501, Kali is at EULAR with the bispecific sibling. KT502 is the simpler molecule, CD19xCD3 with the same CD3 masking, subcutaneous. The trispecific went to Sanofi. The bispecific stays in-house, for now. EULAR is where rheumatology BD scouts go shopping, so the timing reads intentional. KT501 is already in Phase 1a RA. If KT502 enters clinic by year end across SLE or systemic sclerosis, Kali has two shots on B-cell depletion before Cabaletta or Cullinan generates Phase 2 readouts.
005Adjacent Structures
FRONTIER MAP
Sanofi· CD19xBCMAxCD3 trispecific, Kali partnerInnovent Biologics· Chinese CD19xBCMAxCD3 trispecificCullinan Therapeutics· CD19xCD3 TCE, autoimmuneOuro Medicines· BCMAxCD3 TCE for autoimmuneModeX Therapeutics· tetraspecific CD19xCD20xCD28xCD3Commit Biologics· complement-based B cell engagerClimb Bio· anti-CD19 monoclonal, pMN
— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.